Treatment failure attributed to resistance is a major problem in medical oncology.

Across tumor types, the majority of patients with cancer are likely to face treatment resistance at some point.

Learn More

Welcome to OncoGeneX

Recent News

Tuesday, Jun 13 2017

Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Form S-4 Registration Statement Declared Effective by SEC

Monday, May 15 2017

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2017

Tuesday, May 9 2017

OncoGenex to Report First Quarter 2017 Financial Results on May 15, 2017

Twitter Feed

Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance

OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.

Learn more about cancer treatment resistance.


Product Pipeline

Phase 3
OncoGenex’ lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Clusterin is upregulated in tumor cells in response to treatment interventions such as chemotherapy, hormone ablation and radiation therapy and has been found to be overexpressed in a number of cancers, including prostate, lung, breast and bladder. Increased clusterin production has been linked to faster rates of cancer progression, treatment resistance and shorter survival duration.
Phase 2

Apatorsen is a once-weekly intravenous (IV) experimental drug designed to inhibit the production of heat shock protein 27 (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. By inhibiting Hsp27, apatorsen may disable cancer cells’ defenses and overcome treatment resistance. Both the potential single-agent activity and synergistic activity of apatorsen with cancer treatments may increase the overall benefit of existing therapies and augment the durability of treatment outcomes, which could lead to increased patient survival.

External Link Pop Up Window

You are now exiting the OncoGenex Web site and entering a third party Web site.

OncoGenex does not review the information contained on the following Web site for content, accuracy or completeness. Use of and access to the information are subject to the terms, limitations and conditions set by the Web site producer. OncoGenex makes no claims about the accuracy or any other aspect of the information contained on this Web site, nor does OncoGenex necessarily endorse this Web site.

Stay on OncoGenex Continue